These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 38501315)

  • 1. Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.
    Huang SY; Zhang YR; Guo Y; Du J; Ren P; Wu BS; Feng JF; ; Cheng W; Yu JT
    Alzheimers Dement; 2024 May; 20(5):3251-3269. PubMed ID: 38501315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Glymphatic Flow on Diffusion Tensor MRI as a Marker of Neurodegeneration in Alzheimer's Disease: Correlation with Gray Matter Volume Loss and Cognitive Decline Independent of Cerebral Amyloid Deposition.
    Kim M; Song YS; Han K; Bae YJ; Han JW; Kim KW
    J Alzheimers Dis; 2024; 99(1):279-290. PubMed ID: 38669532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glymphatic system impairment in Alzheimer's disease: associations with perivascular space volume and cognitive function.
    Zhang X; Wang Y; Jiao B; Wang Z; Shi J; Zhang Y; Bai X; Li Z; Li S; Bai R; Sui B
    Eur Radiol; 2024 Feb; 34(2):1314-1323. PubMed ID: 37610441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease.
    Kamagata K; Andica C; Takabayashi K; Saito Y; Taoka T; Nozaki H; Kikuta J; Fujita S; Hagiwara A; Kamiya K; Wada A; Akashi T; Sano K; Nishizawa M; Hori M; Naganawa S; Aoki S;
    Neurology; 2022 Dec; 99(24):e2648-e2660. PubMed ID: 36123122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/MRI multimodality imaging to evaluate changes in glymphatic system function and biomarkers of Alzheimer's disease.
    Okazawa H; Nogami M; Ishida S; Makino A; Mori T; Kiyono Y; Ikawa M
    Sci Rep; 2024 May; 14(1):12310. PubMed ID: 38811627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants.
    Hong H; Hong L; Luo X; Zeng Q; Li K; Wang S; Jiaerken Y; Zhang R; Yu X; Zhang Y; Lei C; Liu Z; Chen Y; Huang P; Zhang M;
    Alzheimers Res Ther; 2024 Feb; 16(1):43. PubMed ID: 38378607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of glymphatic system activity by diffusion tensor image analysis along the perivascular space (DTI-ALPS) in dementia patients.
    Liang T; Chang F; Huang Z; Peng D; Zhou X; Liu W
    Br J Radiol; 2023 Jun; 96(1146):20220315. PubMed ID: 37066824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships Between the Deposition of Amyloid-β and Tau Protein and Glymphatic System Activity in Alzheimer's Disease: Diffusion Tensor Image Study.
    Ota M; Sato N; Nakaya M; Shigemoto Y; Kimura Y; Chiba E; Yokoi Y; Tsukamoto T; Matsuda H
    J Alzheimers Dis; 2022; 90(1):295-303. PubMed ID: 36120782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A "glympse" into neurodegeneration: Diffusion MRI and cerebrospinal fluid aquaporin-4 for the assessment of glymphatic system in Alzheimer's disease and other dementias.
    Sacchi L; D'Agata F; Campisi C; Arcaro M; Carandini T; Örzsik B; Dal Maschio VP; Fenoglio C; Pietroboni AM; Ghezzi L; Serpente M; Pintus M; Conte G; Triulzi F; Lopiano L; Galimberti D; Cercignani M; Bozzali M; Arighi A
    Hum Brain Mapp; 2024 Aug; 45(12):e26805. PubMed ID: 39185685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the link between glymphatic function and cortical microstructures in post-traumatic stress disorder.
    Shao Z; Gao X; Cen S; ; Tang X; Gong J; Ding W
    J Affect Disord; 2024 Nov; 365():341-350. PubMed ID: 39178958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study.
    Li Y; Wang L; Zhong J; Xu H; Han Y; ; Zuo C; Jiang J
    Alzheimers Dement; 2024 Sep; 20(9):6542-6555. PubMed ID: 39107995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
    Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the DTI-ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia.
    Steward CE; Venkatraman VK; Lui E; Malpas CB; Ellis KA; Cyarto EV; Vivash L; O'Brien TJ; Velakoulis D; Ames D; Masters CL; Lautenschlager NT; Bammer R; Desmond PM
    J Neuroimaging; 2021 May; 31(3):569-578. PubMed ID: 33556226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological mechanisms of resilience to tau pathology in Alzheimer's disease.
    Svenningsson AL; Bocancea DI; Stomrud E; van Loenhoud A; Barkhof F; Mattsson-Carlgren N; Palmqvist S; Hansson O; Ossenkoppele R
    Alzheimers Res Ther; 2024 Oct; 16(1):221. PubMed ID: 39396028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.